Takeda Pharmaceutical Co. $TAK Shares Bought by AlphaCore Capital LLC

AlphaCore Capital LLC lifted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 216.8% during the third quarter, Holdings Channel reports. The fund owned 39,358 shares of the company’s stock after purchasing an additional 26,933 shares during the quarter. AlphaCore Capital LLC’s holdings in Takeda Pharmaceutical were worth $576,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in Takeda Pharmaceutical by 225.8% in the 2nd quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock valued at $16,035,000 after purchasing an additional 718,805 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares during the last quarter. ABC Arbitrage SA purchased a new stake in shares of Takeda Pharmaceutical during the third quarter worth about $8,372,000. Quantinno Capital Management LP raised its position in shares of Takeda Pharmaceutical by 54.5% in the second quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock valued at $12,322,000 after buying an additional 280,992 shares during the last quarter. Finally, Brandes Investment Partners LP raised its position in shares of Takeda Pharmaceutical by 5.9% in the second quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after buying an additional 208,136 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

TAK has been the topic of a number of analyst reports. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.1%

Shares of NYSE:TAK opened at $18.74 on Friday. The stock has a 50-day simple moving average of $16.94 and a 200-day simple moving average of $15.35. The stock has a market capitalization of $59.61 billion, a P/E ratio of 78.07 and a beta of 0.02. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.82. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The firm had revenue of $6.75 billion for the quarter, compared to analyst estimates of $7.81 billion. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.